Catawba River Capital Purchases 20,006 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Catawba River Capital significantly increased its stake in Regeneron Pharmaceuticals by 206.9% during the 2nd quarter, now holding 29,676 shares worth approximately $15.58 million.
• Regeneron reported an earnings per share (EPS) of $12.89 in its latest earnings release, exceeding the expected $8.43 EPS, with revenue of $3.68 billion for the quarter.
• The company recently declared a quarterly dividend of $0.88 per share, reflecting a dividend yield of 0.6% and a payout ratio of 8.87%.

Catawba River Capital increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 206.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,676 shares of the biopharmaceutical company's stock after acquiring an additional 20,006 shares during the quarter. Regeneron Pharmaceuticals makes up about 7.9% of Catawba River Capital's portfolio, making the stock its 4th biggest holding. Catawba River Capital's holdings in Regeneron Pharmaceuticals were worth $15,580,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares during the last quarter. Activest Wealth Management boosted its position in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $27,000. Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Finally, Colonial Trust Advisors purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 1.3%

NASDAQ REGN opened at $569.17 on Friday. The firm has a 50 day simple moving average of $574.34 and a 200-day simple moving average of $563.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,013.09. The firm has a market cap of $60.33 billion, a price-to-earnings ratio of 14.34, a PEG ratio of 1.85 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the firm posted $11.56 earnings per share. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on REGN. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price objective on the stock. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating on the stock in a report on Friday, October 10th. Citigroup boosted their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a "buy" rating in a report on Monday. Finally, Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $817.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.